Full-Time

Tech@Lilly MQ – MES Implementation Lead

Associate Director

Posted on 7/31/2025

Lilly USA

Lilly USA

10,001+ employees

Global pharmaceutical company developing medicines

No salary listed

Frankfurt, Germany

In Person

On-site presence required.

Category
Process Engineering
Required Skills
Agile
Requirements
  • Bachelor’s degree in Software Engineering, Computer Science, Computer Engineering, or a related field.
  • Minimum of 7+ years of MES implementation experience working in GMP regulated industry.
  • Experience with IT audits, compliance assessments, and remediation activities, including addressing findings and implementing corrective actions.
  • Deep knowledge and experience with MES platforms, such as Rockwell Automation Pharma Suite, Emerson Syncade, Siemens Camstar, or Werum PAS-X.
  • Familiarity with related technologies and standards, including ISA-95, OPC, and data historians.
  • Experience leading end-to-end MES implementation projects in GMP environment, from requirements gathering to deployment, while managing resources, timelines, and risks.
  • Proficient in project management methodologies, such as Agile or Waterfall, to effectively plan, execute, and deliver MES implementation projects.
  • Expertise in integrating MES systems with other enterprise systems, such as ERP (Enterprise Resource Planning) and SCADA (Supervisory Control and Data Acquisition), to ensure seamless data flow and system interoperability.
  • Knowledge of data management principles, including data validation, transformation, migration, and reporting.
  • Strong understanding of manufacturing processes in the pharmaceutical industry.
  • Strong change management skills to drive organizational change, manage resistance, and ensure user adoption of new MES systems and processes.
  • Excellent communication and interpersonal skills to effectively engage and collaborate with stakeholders at all levels, including senior management, department heads, and end-users.
  • Understanding of regulatory requirements in GMP (Good Manufacturing Practice), such as FDA regulations for pharmaceutical manufacturing.
  • Strong analytical and problem-solving skills to identify and resolve technical issues related to MES systems, configurations, or integrations.
  • Ability to troubleshoot system performance, data integrity, or connectivity problems, working collaboratively with IT teams and vendors to implement solutions.
  • Proven leadership abilities to lead cross-functional teams, assign tasks, manage priorities, and foster a collaborative and productive work environment.
  • Experience mentoring and developing team members, promoting their growth and ensuring high-quality deliverables.
  • Understanding of cybersecurity concepts and best practices related to MES technologies.
  • Adaptability and flexibility to work in a fast-paced, dynamic environment and manage multiple tasks simultaneously.
Responsibilities
  • Lead the successful implementation of MES solution across the organization.
  • Leverage deep knowledge of MES, collaborate with cross-functional and global teams, and design tailored solutions to optimize manufacturing processes, enhance compliance and efficiency, and drive overall operational excellence for the site.
  • Take ownership of the end-to-end MES implementation process, including requirements gathering, solution design, configuration, testing, deployment, and ongoing support.
  • Collaborate with stakeholders to analyze business needs, define functional requirements, and design MES solutions that align with organizational goals and industry best practices.
  • Develop and execute comprehensive project plans, including timelines, resource allocation, and risk mitigation strategies, to ensure successful implementation within budget and schedule constraints.
  • Build strong relationships with key stakeholders, including senior management, department functional leaders, and end-users, to understand their requirements, gain buy-in, and ensure seamless adoption of the MES system.
  • Work closely with global IT, operations, automation, engineering, technical services and quality teams to integrate the MES solution with existing systems and processes, ensuring data integrity, system reliability, and scalability.
  • Utilize deep knowledge of MES platforms to configure and customize the system to meet specific business needs, ensuring a tailored solution that maximizes operational efficiency.
  • Develop training programs and materials to educate end-users on the effective utilization of the MES system. Create comprehensive documentation, including user guides, standard operating procedures, and technical specifications.
  • Stay abreast of industry trends, emerging technologies, and best practices related to MES implementation. Identify opportunities for process improvements, system enhancements, and operational optimizations.
  • Lead ongoing support, troubleshooting, and maintenance of the MES system, ensuring the highest level of system availability and performance.
  • Bridge the gap between technical expertise and business requirements, translating complex concepts into understandable terms for diverse audiences.
  • Define and lead the governance of the execution of the MES agenda including items like communication plan to stakeholders, prioritization, scorecard, promotion of program to the global organization and site employees, etc.
  • Represent Alzey in the global MES forums providing visibility of local needs, concerns.
  • Ensure MES system is in compliance with industry-specific regulations, such as FDA guidelines and GMP requirements, Lilly corporate policy and procedures, and local procedures to maintain product quality and safety.
  • Develop and execute comprehensive testing strategies, including unit testing, system integration testing, and user acceptance testing, to validate the functionality, performance, and reliability of the MES system.
  • Act as MES System Custodian ensuring the compliant and reliable operation of the MES system, maintaining data integrity, managing system configurations, supporting validation activities, and driving continuous improvement in line with GMP requirements.
  • Collaborate with internal and external auditors to facilitate MES audits and inspections, addressing any findings promptly.
Desired Qualifications
  • Master’s degree in Computer Science, Information Technology, Business Administration, or a related field is preferred.
  • Exposure to international operations, diverse teams, global IT projects, or working in a global organization.
  • Proficiency in German and strong English language skills.

Lilly is a global pharmaceutical company that discovers, develops, and sells prescription medicines to improve health outcomes. It grows its portfolio through extensive research and development, then manufactures and distributes drugs worldwide to healthcare providers who prescribe them to patients. Lilly’s products span diabetes, cancer, immunology, pain management, and other serious conditions, including diabetes treatments tirzepatide and dulaglutide. The company emphasizes safety, efficacy, and ethical practices, and protects its products from counterfeiting while partnering with organizations such as Team USA. Its approach relies on rigorous R&D, strong manufacturing, and a global distribution network to bring medicines to patients. Lilly’s goal is to help people live better lives by delivering reliable medical solutions through a global, ethical, and quality-focused operation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Indianapolis, Indiana

Founded

1876

Simplify Jobs

Simplify's Take

What believers are saying

  • International Mounjaro sales jumped to $4.4 billion in Q1 from China's reimbursement list.
  • $4.5 billion Lebanon API plant opens 2027, producing tirzepatide and retatrutide at largest scale.
  • Acquires Scorpion's PI3Kα inhibitor, bolstering oncology pipeline beyond Verzenio.

What critics are saying

  • Novo Nordisk's Wegovy scaling erodes Lilly's US GLP-1 share below 25% into 2027.
  • FDA scrutiny delays Foundayo launch after May 4 hepatic failure, losing $2-3B Q4 revenue.
  • Shareholder demands force independent board chair, dropping stock 10-15% in 12 months.

What makes Lilly USA unique

  • Mounjaro generated $8.66 billion in Q1 2026 sales, surpassing Keytruda as world's best-selling drug.
  • Launched first genetic medicine facility in Lebanon on May 6, 2026, for Alzheimer's and ALS.
  • Partnered with Profluent Bio for up to $2.25 billion AI-driven DNA editing tools on May 5.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Flexible Work Hours

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-4%

2 year growth

-4%
The Lebanon Reporter
May 7th, 2026
Lilly invests additional $4.5B in LEAP district, opens first genetic medicine facility

Eli Lilly has announced an additional $4.5 billion investment in its Lebanon, Indiana facilities, bringing its total investment in the LEAP Innovation and Research district to $21 billion. The company opened its first Advanced Therapies site on Wednesday, marking the first operational facility in the 9,000-acre LEAP district. The new funding will support Lilly's Advanced Therapies laboratory and an active pharmaceutical ingredient facility expected to open in 2027. The Advanced Therapies site is Lilly's first dedicated genetic medicine manufacturing facility, focusing on molecular-level research for diseases including Alzheimer's, Parkinson's and ALS. Lilly is developing three facilities across 800 acres in LEAP, including a Medicine Foundry. The Advanced Therapies facility aims to accelerate delivery of breakthrough genetic medicines to patients.

AI Software Services
May 5th, 2026
Unlocking AI innovation in finance medicine and music.

Unlocking AI innovation in finance medicine and music. Published on May 05, 2026 GENETIC MEDICINE REVOLUTION: AI AND BIOTECH JOIN FORCES. In a groundbreaking partnership, Lilly and AI-driven Profluent Bio are teaming up in a deal worth up to $2.25 billion to develop advanced DNA editing tools. Their goal? To create precise treatments for genetic conditions that currently lack effective solutions, using innovative AI models to design enzymes that can target multiple mutations in the genome. This collaboration aims to unlock the "holy grail" of genetic medicine through kilobase-scale DNA editing. This matters because it could transform how AI Software Services treat genetic diseases, offering hope to millions who suffer from conditions deemed untreatable. The tools being developed are likely to be accessible, lowering barriers to entry in a field that has traditionally been expensive and exclusive. Imagine a startup that provides a platform for creators and developers to access these AI-driven genetic editing tools, enabling them to innovate and create personalized therapies. This could attract investors eager to support the next wave of medical breakthroughs!

The Economic Times
May 4th, 2026
French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly.

French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly. The ANSM fined Novo Nordisk 783,838 euros regarding adverts for Wegovy and also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." * Updated On May 4, 2026 at 05:54 PM IST Paris: France's medicine safety agency ANSM said Monday it had imposed fines on pharmaceutical firms Novo Nordisk and Eli Lilly over their advertising campaigns on obesity. The agency fined on Novo Nordisk France 1.78 million euros ($2.08 million) - a million relating to adverts promoting its Saxenda drug and 783,838 euros regarding adverts for Wegovy weight management medication for treating obesity. The ANSM also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." French laws prohibit any advertising to the general public of the treatments. The national medicines regulator said that the fines aimed to "prevent any communication likely to promote the use of drug treatment as the principal response to obesity, to encourage the public to request this treatment from a healthcare professional or seek to obtain it themselves." Event. * Fri, 24 Jul 2026 * Le Meridien, Hyderabad The ANSM said the advertising campaigns were "likely to mislead the public in a context marked by extensive media coverage" as well as what it termed growing inappropriate use of medications which activate certain hormones in order notably to reduce appetite,and aid weight loss. In a statement to AFP, Novo Nordisk France said it "strongly contests" the ANSM's finding, adding it is "exploring all possible appeal avenues against this decision". Lilly France said it noted ANSM's decision, while stating it believes its awareness campaign entitled "Obesity is a sick person's problem" from a year ago was "in line with the framework applicable to communications relating to human health". According to a French study published in 2024, around 18 percent of the French population - equivalent to some ten million people - are obese.

NBC News
Apr 14th, 2026
FDA requests more safety data from Lilly on weight loss pill Foundayo

The FDA is requesting additional safety data from Eli Lilly for its weight loss pill Foundayo, including information on potential heart and liver problems, according to the approval letter published Tuesday. The agency wants more data on risks including heart attacks, strokes, drug-induced liver injuries and delayed stomach emptying. Foundayo, approved this month under a fast-track pilot programme, is the second oral GLP-1 to reach market after Novo Nordisk's Wegovy pill. The FDA is also asking Lilly to collect thyroid cancer risk data for at least 15 years. The requests are considered routine for newly approved drugs, particularly for orforglipron, Foundayo's active ingredient, which has less safety data than older GLP-1s. Lilly must also establish registries tracking children with obesity and pregnancy outcomes.

PR Newswire
Apr 14th, 2026
Vasa Therapeutics partners with Lilly TuneLab to accelerate AI-driven CAMKII inhibitor development

Vasa Therapeutics, a clinical-stage biopharmaceutical company, has partnered with Eli Lilly to use Lilly TuneLab, an AI-enabled drug discovery platform that provides access to models trained on Lilly's proprietary research data. Vasa will use the platform to accelerate development of its CAMKII delta inhibitor, which is planned for Phase 1 clinical trials in 2027. The company's VS-041 is currently in a proof-of-mechanism trial for heart failure, whilst VS-214 is on track for first-in-human trials in 2026. The platform uses federated learning, allowing companies to access Lilly's AI models whilst maintaining data privacy. Vasa will contribute its own experimental datasets to support the platform's improvement. The company focuses on developing therapies for cardiovascular, neuromuscular and age-related disorders.

INACTIVE